ANI Pharmaceuticals Posts Record Q2 Revenue of $266M and Reaffirms Full-Year Outlook

summarizeSummary

Record Q2 2026 revenue of $266 million, up 25.9% year-over-year, was accompanied by a reaffirmed full-year guidance. Cortrophin Gel revenue grew 43.5% to $117.1 million, and early momentum from the gout expansion is positive.

check_boxKey Events · Earnings and Guidance · ANIP

• Record Q2 Revenue of $266M

  Total net revenues climbed 25.9% year-over-year to $266.0 million, fueled by Cortrophin Gel (up 43.5% to $117.1M) and Generics (up 9.7% to $99.1M).

• Adjusted EBITDA Jumps 32.4%

  Adjusted non-GAAP EBITDA reached $71.6 million, a 32.4% increase, with adjusted diluted EPS of $2.21 compared to $1.80 a year ago.

• Full-Year Guidance Reaffirmed

  Management reiterated 2026 total revenue guidance of $1,080–$1,140 million and adjusted EBITDA of $285–$300 million, while modestly lowering Cortrophin Gel revenue guidance to $520–$540 million (from $540–$575M).

• Gout Expansion Fully Operational

  The expanded Rare Disease sales force targeting acute gouty arthritis flares was fully deployed by the end of June; early indicators show over 95% of reps generating multiple new patient cases.

auto_awesomeAnalysis · ANIP · Life Sciences

A strong quarter was driven by 25.9% revenue growth, anchored by the lead rare disease drug Cortrophin Gel, which surged 43.5%. Reaffirming the full-year outlook underscores management's confidence in the ongoing gout expansion and pipeline progress. The modest trim to Cortrophin Gel guidance—now $520–$540M—reflects a more conservative ramp but still implies 50–55% growth. With $360M in cash and a new $100M buyback authorization, the balance sheet comfortably supports both investment and shareholder returns.